Allogene Therapeutics to Host Events at American Society of Hematology Annual Meeting 2026 Highlighting the Potential of Allogeneic CAR T to Expand Patient Access
Key Highlights
- ➤Allogene to present new physician market research from a 152-physician survey at ASH 2026
- ➤ALPHA3 is the first registrational trial evaluating MRD-guided first-line consolidation with cema-cel
- ➤ALPHA3 evaluates cema-cel in high-relapse-risk LBCL patients after remission
- ➤New market research findings will appear in a Blood supplement alongside ASH 2026
Expert Statements
Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene Therapeutics
“For too long, we've allowed the realities of the autologous CAR T delivery model to limit our vision of what's possible.”
Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene Therapeutics
“The time has come to change that.”
Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene Therapeutics
“Our new physician research points to an opportunity that extends beyond overcoming today's stubborn access barriers.”
Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene Therapeutics
“When physicians have an actionable treatment option, their willingness to test for MRD increases.”
Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene Therapeutics
“When CAR T can potentially be delivered closer to patients, doors may open to broader adoption.”
Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene Therapeutics
“With cema-cel and ALPHA3, we are pursuing both – bringing CAR T earlier in the treatment journey and potentially expanding where patients can receive it.”
Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene Therapeutics
“At ASH, we want to challenge the industry to think bigger about what CAR T can become.”
* Company to Host In-Person Event at ASH 2026 Featuring New Market Research and a Physician Panel Discussion on Barriers to CAR T Access, Community Adoption in Large B-Cell Lymphoma (LBCL), and the Potential Role of Cemacabtagene Ansegedleucel (Cema-cel) to Expand Patient Access * New Market Research Findings to be Published in a Supplement to Blood in Conjunction with the ASH Annual Meeting * ALPHA3, the First Registrational Trial Evaluating Minimal Residual Disease (MRD)-Guided First-Line Consolidation with Cema-cel, to Be Featured at Natera-Hosted Clinical Trial Showcase SOUTH SAN FRANCISCO, Calif., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced its participation in the 68(th) American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans. Allogene’s activities at ASH will highlight the potential of allogeneic CAR T to expand patient access through new physician market research and expert discussions on barriers to treatment. Additionally, the Company’s pivotal ALPHA3 trial, evaluating cemacabtagene ansegedleucel (cema-cel) as minimal residual disease (MRD)-guided first-line consolidation therapy for patients with large B-cell lymphoma (LBCL), will be featured at a clinical trial showcase hosted by Natera.
Get started
Create a free account to read the full story.
